新抗原市场基于(关键区域、市场参与者、规模和份额)- 预测至 2028 年

  • Report Code : TIPRE00021781
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 151
Buy Now

Neoantigens Market Global Analsyis and Forecast 2028

Buy Now

 

2023 年新生抗原市场价值为 2,71,428.57 万美元,预计到 2028 年将达到 10,54,783.54 万美元;预计 2023 年至 2028 年的复合年增长率为 31.2%。

 

新抗原是最近开发的抗原,过去免疫系统从未检测到过。肿瘤蛋白的改变可能导致由突变或病毒蛋白引起的新抗原的产生。新抗原用于癌细胞的选择性治疗。新抗原市场
根据治疗、治疗专业和地理位置进行细分。根据地理位置,市场分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。该报告提供了对新抗原市场的见解和深入分析,强调了各种参数,例如市场趋势、技术进步、市场动态和全球主要市场参与者的竞争格局分析。它还包括所有地区的 COVID-19 影响分析。据估计,市场在预测期内可能会保持稳定的增长率。

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

新生抗原市场:

肿瘤新抗原市场

  • 复合年增长率(2023 - 2028)
    31.2%
  • 2023 年市场规模
    2.7143 亿美元
  • 市场规模 2028 年
    10.5478 亿美元

市场动态

增长动力
  • 財政部
  • 財政部
  • 財政部
未来的趋势
  • 財政部
  • 財政部
  • 財政部
机会
  • 財政部
  • 財政部
  • 財政部

关键人物;主力;重要一员

  •  
  • 阿基里斯治疗公司
  • Advaxis 公司
  • 框架癌症治疗公司
  • 热那亚
  • Gradalis 公司
  • 砂岩肿瘤学
  • 免疫学公司
  • 麦迪基因公司
  • Ziopharm Oncology 公司

区域概况

  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

治疗
  • 联合治疗和单一治疗
治疗专科
  • 胃肠道癌症
  • 肺癌
  • 实体肿瘤
  • 泌尿系统癌症
  • 黑色素瘤
  • 头颈癌
  • 其他的
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

 

 

市场洞察

 

 

抗癌新抗原疫苗的进展

 

生物技术的发展使免疫疗法的接受度不断提高,进一步推动了其在个性化医疗中的应用。免疫疗法被广泛用于治疗癌症;一些免疫疗法程序涉及使用新抗原,即癌细胞表面的抗原。因此,新抗原的应用正在被广泛研究以治疗癌症。新抗原的独特性使研究人员能够识别患者的免疫系统并找到抗原以靶向癌细胞而不会干扰健康细胞。2015
年首次进行新抗原疫苗临床试验后,免疫疗法的发展开始加快步伐。2017 年,Neon Therapeutics 发表了另外两项临床试验研究,证明了新抗原疫苗对治疗人类黑色素瘤(皮肤癌)的有效性。临床试验的积极结果吸引了各种初创公司来发现和开发基于新抗原的癌症疗法。许多公司对新抗原的开发表现出兴趣。以下是参与新抗原开发的几家公司的例子。

  • BioNTech SE 是一家在肿瘤抗原疫苗市场运营的德国公司。BioNTech SE 开发了个性化抗癌疫苗 (IVAC) Mutanome 平台,该平台可对 RNA 分子进行改造以生产定制肿瘤抗原疫苗。针对三阴性乳腺癌、多种肿瘤类型和黑色素瘤的 IVAC 临床试验正在进行中。
  • Genocea Biosciences 的 ATLAS 平台采用体外方法开发新抗原疫苗。Genocea Biosciences 已从 Polaris Partners、葛兰素史克和强生创新等投资者那里筹集了约 9100 万美元资金,用于开发其新抗原癌症疫苗 — GEN-009。该疫苗目前处于 1a/2 期临床试验阶段,旨在治疗黑色素瘤、肺癌和癌症。
  • Gritstone Oncology 利用其 AI 平台 EDGE,通过计算机模拟方法开发新抗原疫苗。该公司已开发了两种产品 GRANITE-001 和 SLATE-001。GRANITE-001 被设计为基于患者特定肿瘤类型的个体治疗,而 SLATE-001 则被配制成一种常见的新抗原疫苗,可用于显示类似新抗原的多名患者。
  • Agenus Inc. 开发了 AutoSynVax (ASV) 新抗原疫苗,该疫苗与佐剂 QS-21 Stimulon 配合使用,可治疗实体肿瘤。目前 ASV 正在美国进行 1 期临床试验。
  • 自 2016 年以来,Moderna, Inc. 一直参与其个性化癌症疫苗 (PCV) mRNA-4157 与默克公司的 Keytruda 联合使用的临床试验。2020 年 11 月,Moderna, Inc. 发布了有关其癌症疫苗的最新消息,称 mRNA-4157 与 Keytruda 联合使用在所有剂量水平下均具有良好的耐受性,并且已在患者身上产生反应。

抗癌新抗原疫苗的此类发展正在推动市场增长。

 

 

基于治疗的见解

 

根据治疗方式,肿瘤新抗原市场分为联合治疗和单一治疗。预计到 2023 年,联合治疗领域将占据更大的市场份额。不过,单一治疗领域预计在预测期内将实现更快的增长。

 

基于治疗专业的见解

 

根据治疗专长,新抗原市场细分为胃肠道癌症、肺癌、实体瘤、泌尿系统癌症、黑色素瘤、头颈癌等。预计 2023 年胃肠道癌症领域将占据最大的市场份额,并有望在未来几年以最快的速度增长。

市场参与者高度采用无机策略来满足不断变化的客户需求并保持其改进的服务。例如,2021 年 1 月,Genocea 宣布发表癌症发现论文,这得益于使用 ATLAS 平台进行新抗原识别的好处。这一发现通过理论上确保新抗原免疫疗法靶向正确的新抗原同时去除抑制剂,增强了新抗原免疫疗法。

 

新生抗原市场报告范围

报告属性细节
2023 年的市场规模2.7143亿美元
2028 年市场规模10.5478亿美元
全球复合年增长率(2023 - 2028)31.2%
历史数据2021-2022
预测期2024-2028
涵盖的领域按治疗
  • 联合治疗和单一治疗
按治疗专业
  • 胃肠道癌症
  • 肺癌
  • 实体肿瘤
  • 泌尿系统癌症
  • 黑色素瘤
  • 头颈癌
  • 其他的
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  •  
  • 阿基里斯治疗公司
  • Advaxis 公司
  • 框架癌症治疗公司
  • 热那亚
  • Gradalis 公司
  • 砂岩肿瘤学
  • 免疫学公司
  • 麦迪基因公司
  • Ziopharm Oncology 公司
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

 

 

按治疗

 

  • 联合治疗
  • 单一疗法

 

按治疗专业

 

  • 胃肠道癌症
  • 肺癌
  • 实体肿瘤
  • 泌尿系统癌症
  • 黑色素瘤
  • 头颈癌
  • 其他的

 

按地理位置

 

  • 北美
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 法国
    • 德国
    • 意大利
    • 英国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳大利亚
    • 亚太地区其他地区
  • 中东和非洲 (MEA)
    • 南非
    • 沙特阿拉伯
    • 阿联酋
    • MEA 其他地区
  • 南美洲和中美洲(SCAM)
    • 巴西
    • 阿根廷
    • 其余的骗局

 

公司简介

 

  • 阿基里斯治疗公司
  • Advaxis 公司
  • 框架癌症治疗公司
  • Genocea,Gradalis,Inc.
  • 砂岩肿瘤学
  • 免疫学公司
  • 麦迪基因公司
  • Ziopharm Oncology 公司
  • Moderna 公司
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


How many neoantigens are commercialized?

Several companies into clinical trial phases for their respective neoantigens. It is expected that by 2023, companies will commercialize their products in the market. In addition, it is expected that the cost of neoantigens will be much higher than cancer vaccines.

What are the driving factors for the neoantigens market across the globe?

Key factors that are driving growth of the market are developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, possible side effects associated with neoantigen vaccines are likely to hinder the growth of the neoantigens market.

What is are Neoantigens?

Neoantigens are recently developed antigens that have not been detected by the immune system historically. Alterations in tumor proteins may result in the development of neoantigens caused by mutations or viral proteins. Neoantigens are used in selective treatments for cancerous cells.

The List of Companies - Neoantigens Market

  1. Achilles Therapeutics plc
  2. Advaxis, Inc.
  3. Frame Cancer Therapeutics
  4. Genocea
  5. Gradalis, Inc.
  6. Gritstone Oncology
  7. Immunicum AB
  8. Medigene AG
  9. Ziopharm Oncology, Inc.
  10. Moderna, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports